FDA Requests Belviq Be Pulled From The US Market Due To Cancer Risk
Executive SummaryThe agency requested the weight loss pill be voluntarily recalled by Eisai, the death knell for a trio of obesity drugs that launched early in the last decade.
You may also be interested in...
The view from 2020: Scrip looks back over the last decade at the drug launches that defied expectations – for the worse.
The Japanese pharma says it will discuss the data with US FDA, with hopes of potential to incorporate secondary endpoint data in labeling.
Arena's valuation rose more than four-fold in 2017. CEO Amit Munshi discusses his plans for lead programs ralinepag and etrasimod following cost cutting and fundraising, and handing over rights to weight loss product Belviq to Eisai.